FDA warns medispa against stem cell process

The FDA warned a medical spa in Pennsylvania that it violated agency rules by significantly changing adipose tissue for procedures including breast augmentation. Stem cells derived from a patient's structural or adipose tissue may be injected into that patient as long as the cells' structure is only minimally changed. Processes that greatly change adipose tissue are more stringently regulated.

View Full Article in:

Cosmetic surgery practice s stem cell use runs afoul of FDA - MedCityNews.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC